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Alterations in Ca2 signaling may contribute to tu-
morigenesis and the mechanism of action of some anti-
cancer drugs. The plasma membrane calcium-ATPase
(PMCA) is a crucial controller of intracellular Ca2 sig-
naling. Altered PMCA expression occurs in the mam-
mary gland during lactation and in breast cancer cell
lines. Despite this, the consequences of PMCA inhibition
in breast cancer cell lines have not been investigated. In
this work, we used Tet-off PMCA antisense-expressing
MCF-7 cells to assess the effects of PMCA inhibition in a
human breast cancer cell line. At a level of PMCA inhi-
bition that did not completely prevent PMCA-mediated
Ca2 efflux and did not induce cell death, a dramatic
inhibition of cellular proliferation was observed. Fluo-
rescence-activated cell sorting analysis indicated that
PMCA antisense involves changes in cell cycle kinetics
but not cell cycle arrest. We concluded that modulation
of PMCA has important effects in regulating the prolif-
eration of human breast cancer MCF-7 cells.
Free intracellular Ca2, acting as a second messenger, is
crucial for a diverse range of biological functions, such as fer-
tilization, neurotransmission, muscle contraction, and gene
transcription (1, 2). Intracellular Ca2 signaling is also a key
regulator of proliferation (3), cell cycle progression (4), and
apoptosis (5). Modulation of capacitative Ca2 entry, a mech-
anism whereby the influx of extracellular Ca2 is coupled to
the depletion of intracellular Ca2 stores within the endoplas-
mic reticulum, is associated with the proliferative phenotype
(6). Indeed, blockers of Ca2 entry may be potential anti-pro-
liferative agents (7, 8). Inhibition of Ca2/calmodulin-depend-
ent serine/threonine protein kinase II also arrests HeLa cells in
the G2 phase of the cell cycle (9), and apoptotic resistance
conferred by overexpression of the anti-apoptotic oncoprotein
Bcl-2 involves modulation of Ca2 handling by the endoplasmic
reticulum (5) and capacitative Ca2 entry (10, 11). Although
the essential role of Ca2 signaling in maintaining homeostatic
functions is well established, less is known about the role of
aberrant Ca2 signaling in disease (12, 13).
The plasma membrane Ca2-ATPase (PMCA),1 or pump,
belongs to the family of P-type ATPases and is a critical
regulator of free intracellular Ca2 (14). It actively extrudes
Ca2 across the plasma membrane and is important for
maintaining basal cytosolic Ca2 levels and lowering free
intracellular Ca2 after the generation of Ca2 transients
and other Ca2 signaling events (2, 15). PMCA has important
roles in shaping the dynamics of Ca2 signaling, as its acti-
vation can limit Ca2 influx during capacitative Ca2 entry
(16). Moreover, PMCA overexpression decreases both the am-
plitude and duration of cytosolic Ca2 responses after ago-
nist-induced stimulation (17).
There are four isoforms of PMCA (PMCA1–4) with addi-
tional isoform diversity generated by alternative splicing
from the primary PMCA transcripts (14, 18). Up-regulation
of PMCA2 and down-regulation of PMCA4 in the rat mam-
mary gland during lactation may indicate that PMCA iso-
forms regulate differentiation and proliferation of the mam-
mary gland (19).
There is also an increasing awareness that PMCA alter-
ations are associated with tumorigenesis, including that of the
mammary gland (20). Indeed, relative PMCA1 mRNA expres-
sion is greater in tumorigenic breast cancer MCF-7 and MDA-
MB-231 cells than that in non-tumorigenic MCF-10A cells (21).
PMCA1 and PMCA4 expression is also lower in simian virus
40-transformed human skin fibroblasts (22). Thus, perturbed
PMCA regulation or function may be important in diseases
such as cancer. Therapeutic modulation of PMCA expression
and/or activity may have functional consequences in suppress-
ing the tumorigenic phenotype. The appropriateness of PMCA
as a possible drug target is also demonstrated by the promi-
nence of other clinically used inhibitors of P-type ATPases,
digoxin and omeprazole, as inhibitors of Na/K-ATPase and
H/K-ATPase, respectively (23, 24).
Despite the dynamic regulation of PMCA expression in the
mammary gland, the consequences of PMCA inhibition in
breast cancer cell lines has not been addressed. Our aim was
to investigate whether PMCA inhibition alters Ca2 homeo-
stasis, cell proliferation, and cell death in MCF-7 human
breast cancer cells.
EXPERIMENTAL PROCEDURES
Cell Culture—MCF-7 Tet-off cells (Clontech) were grown in Dulbec-
co’s modified Eagle’s medium supplemented with 10% fetal bovine
serum, 4 mM L-glutamine, 100 g/ml G418, 100 units/ml penicillin G,
and 100 g/ml streptomycin with the addition of 110 g/ml hygromycin
B and 100 ng/ml doxycycline (DOX) as required. All cultures were
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maintained at 37 °C in a humidified 5% CO2/95% air incubator.
Construction of PMCA Antisense cDNA and Cloning—A 286-base-
pair cDNA fragment was amplified by reverse transcription-PCR from
MCF-7 Tet-off cells and cloned into the bidirectional pBI-G response
plasmid (Clontech) to generate the PMCA antisense construct. The
following primers were used to amplify the cDNA fragment: forward
primer, 5-TAGGTCGACGAAATGTCTATGACAGCAT-3; and reverse
primer, 5-TAGGTCGACGGGCCCATTATCTTCTTCATCAT-3. These
primers were based on sequence information that is conserved across
all human PMCA isoforms. A SalI restriction enzyme site (italics) was
introduced into each primer to facilitate cloning, and an ApaI site
(underlined) was incorporated into the reverse primer to assist in di-
rectional cloning. The PCR product was digested with SalI and inserted
into the SalI site of the pBI-G plasmid in the antisense orientation.
Following nucleotide sequencing of the antisense construct, the cDNA
fragment sequence was compared against GenBankTM using BLAST
version 2.2.8.
Generation of a Double Stable MCF-7 Tet-off PMCA Antisense-
transfected Cell Line—Parental MCF-7 Tet-off cells already stably
transfected with the regulatory tetracycline-controlled transactivator
were co-transfected using Lipofectamine 2000 (Invitrogen) with the
prepared pBI-G PMCA antisense plasmid and the pTK-Hyg hygro-
mycin B resistance plasmid (Clontech). Hygromycin B-resistant
clones were isolated (total of 43) and screened for tetracycline-regu-
lated -galactosidase expression. -Galactosidase acted as an indirect
reporter for the simultaneous expression of PMCA antisense RNA
when DOX was removed from the culture medium. Screening was
performed using the -galactosidase enzyme assay system with re-
porter lysis buffer in accordance with the manufacturer’s instructions
(Promega, Annandale, New South Wales, Australia). Eight colonies
that showed differing degrees of tetracycline-regulated -galactosid-
ase activity (2–10-fold increases upon DOX removal) were further
screened for their effect on PMCA protein with the non-isoform-
specific PMCA antibody 5F10. From these colonies, three clones were
assessed in subsequent proliferation assays and from the three, one
clone (A7) was selected for more detailed characterization.
Proliferation Assays—Cells were plated at 800 cells/well in 96-well
plates by initially seeding them in DOX- and hygromycin B-free me-
dium (100 l/well). DOX was then added to or omitted from the wells at
the time of plating (day 0). The cells were grown over a 2-week period
with the medium renewed every 2–3 days, except on the last day of the
experiment. The proliferation of viable cells was monitored daily from
days 3 to 13 via a colorimetric MTS assay (25) by directly adding
CellTiter 96® AQueous One Solution reagent (20 l; Promega) to each
well and incubating plates for 2 h at 37 °C in a humidified 5% CO2/95%
air environment. After 2 h, absorbances were read at 490 nm with a
Bio-Rad Model 550 microplate reader.
Immunoblotting—Protein was isolated from cells plated into 10-cm
diameter dishes at 1  105 cells/dish. The cells were seeded in DOX-
and hygromycin B-free medium and then were adjusted at the time of
plating to include hygromycin B, either with or without DOX (100
ng/ml). On days 3, 7, and 13, the cells were trypsinized and stored as cell
pellets at 80 °C until further processing for total protein isolates.
Total protein was analyzed by immunoblotting, as described previously
(26). For each sample, 40 g of total protein was loaded onto 7.5% gels.
Antibodies were used at the following dilutions and incubated for 1 h at
room temperature: 1:2000 for 5F10 (Affinity BioReagents, Golden, CO),
1:1000 for JA9 (kind gift from Dr. John T. Penniston, Department
Biochemistry and Molecular Biology, Mayo Foundation, Rochester,
MN), 1:1000 for NR1 (Affinity BioReagents), 1:1000 for NR2 (Affinity
BioReagents), 1:1000 for IID8 (Affinity BioReagents), and 1:10,000 for
anti--actin (AC-15, Sigma). A goat anti-mouse or goat anti-rabbit IgG
horseradish peroxidase-conjugated secondary antibody (Bio-Rad) was
diluted 1:2000 or 1:1000, respectively, and used as required with incu-
bations for 1 h at room temperature. Proteins were visualized via
enhanced chemiluminescence (ECLTM, Amersham Biosciences). Densi-
tometry measurements of immunoblot bands were analyzed using
MetaMorph® version 4.01 imaging software (Universal Imaging Cor-
poration, Downingtown, PA). For each immunoblot, the optical density
values for bands representing total PMCA, PMCA4, PMCA1, PMCA2,
and SERCA2 were normalized to the corresponding value for the -ac-
tin band in each lane.
Fluorescence-activated Cell Sorting (FACS) Analysis of DNA Con-
tent—Cells were plated at 5  105 cells/dish in 10-cm diameter dishes,
in DOX- and hygromycin B-free medium and then grown in either the
presence or absence of DOX. On days 7 and 13, the cells were harvested
from the dishes by collecting trypsinized cells together with floating
cells in the medium. For each condition, a volume of the cell suspension
corresponding to 2  106 cells was centrifuged, and the resultant cell
pellet was resuspended in ice-cold phosphate-buffered saline (0.5 ml).
The cells were fixed in ice-cold 70% ethanol and stained with propidium
iodide. FACS analysis was performed using a BD Biosciences FACS-
CaliburTM flow cytometer. DNA content histograms and cell cycle phase
distributions were modeled from at least 10,000 single events by ex-
cluding the cell aggregates based on scatter plots of the fluorescence
pulse area versus fluorescence pulse width using ModFit LTTM version
2.0 (Mac) software (Verity Software House, Topsham, ME).
5-Bromo-2-deoxyuridine (BrdUrd) Pulse-Chase Analysis of Cell Cy-
cle Progression—Cells that had been growing in the presence or absence
of DOX-containing medium for 6 days were plated at 1  106 cells/dish
in 10-cm diameter dishes. After a further 24 h in the appropriate
medium (DOX), the cells were pulsed with either Dulbecco’s phos-
phate-buffered saline or 5-bromo-2-deoxyuridine 10 M (BrdUrd) for
1 h, followed by one wash with Dulbecco’s phosphate-buffered saline.
After washing, the cells were then maintained in the appropriate me-
dium (DOX) until being trypsinized, centrifuged at 300  g for 5 min,
and fixed at 0, 3, 6, 12, and 24 h post-BrdUrd pulse. Collected cells were
fixed and stained with the BD Biosciences fluorescein isothiocyanate
BrdUrd flow kit, according to the manufacturer’s instructions. Briefly,
paraformaldehyde-fixed and saponin-permeabilized cells were incu-
bated for 1 h at 37 °C with DNase (300 g/ml in Dulbecco’s phosphate-
buffered saline). BrdUrd and total DNA were then stained with a
fluorescein isothiocyanate-conjugated anti-BrdUrd antibody and 7-ami-
no-actinomycin D (7-AAD), respectively. Data were acquired using a BD
Biosciences FACSCaliburTM flow cytometer with BD Biosciences
CellQuestTM version 3.3 software. For each sample, data were displayed
using WinMDI version 2.8 (Joseph Trotter, facs.scripps.edu/soft-
ware.html) by first gating at least 10,000 events to select a population
of single cells based on density plots of the 7-AAD fluorescence pulse
area (FL3-A) versus the 7-AAD fluorescence pulse width (FL3-W). Us-
ing this subpopulation of cells, density plots of fluorescein isothiocya-
nate-conjugated anti-BrdUrd antibody fluorescence pulse height
(FL1-H) versus 7-AAD fluorescence pulse height (FL3-H) were gener-
ated. Negative BrdUrd controls, where cells were pulsed with Dulbec-
co’s phosphate-buffered saline, were used to set the positions of quad-
rant markers.
Assessment of Cell Morphology—Double stable MCF-7 Tet-off PMCA
antisense-transfected cells were plated onto 25-mm diameter coverslips
placed in a 6-well plate at 1.8  104 cells/well and grown either in the
presence or absence of DOX. On day 13 of the culture, phase contrast
images at 200magnification were taken from five random fields using
a Nikon Eclipse TE300 microscope (Nikon Instech, Kawasaki, Japan)
and MetaFluor® version 4.01 imaging software (Universal Imaging
Corporation, Downingtown, PA).
Assessment of Calcium Efflux—The efflux of free intracellular Ca2
was assessed using a fluorescence microplate reader to monitor the rate
of decline in free intracellular Ca2 concentration ([Ca2]i) after the
generation of ionomycin-induced Ca2 transients that ranged in mag-
nitude with varying concentrations of the Ca2 ionophore. Subconfluent
double stable MCF-7 Tet-off PMCA antisense cells grown in DOX were
subcultured at a split ratio of 1:10 into new T-75 cm2 flasks containing
fresh medium, either with or without DOX (100 ng/ml), and grown for
6 days. After 6 days, the cells were plated into polystyrene 96-well
plates at 4  104 cells/well in growth medium (100 l/well) with or
without DOX, as previously treated. The cells were allowed to adhere
for 24 h before loading the cells with the non-ratiometric Ca2 indicator
fluo-4 AM (8 M; Molecular Probes, Eugene, OR) in the loading buffer.
The loading buffer (pH 7.3) was composed of 5.9 mM KCl, 1.4 mMMgCl2,
10 mM HEPES, 1.2 mM NaH2PO4, 5 mM NaHCO3, 140 mM NaCl, 11.5
mM glucose, 1.8 mM CaCl2, and 3 mg/ml bovine serum albumin. The
cells were loaded at 37 °C for 30 min and washed once with loading
buffer (no indicator) and once with physiological salt solution (PSS).
PSS (pH 7.3) contained 5.9 mM KCl, 1.4 mM MgCl2, 10 mM HEPES, 1.2
mM NaH2PO4, 5 mM NaHCO3, 140 mM NaCl, 11.5 mM glucose, and 1.8
mM CaCl2. The cells were then incubated for 15 min in PSS at room
temperature (21  2 °C) to minimize indicator leakage and sequestra-
tion into intracellular organelles. The PSS was removed, and the cells
were washed once with loading buffer and then twice with PSS in which
NaCl was replaced with an equimolar amount of N-methyl-D-glucamine
and CaCl2 was excluded (Na
/Ca2-free PSS). Cells loaded with fluo-4
were stimulated with 50–420 nM ionomycin in Na/Ca2-free PSS
containing 100 M BAPTA (Molecular Probes) and 5 M cyclopiazonic
acid to obtain various levels of peak [Ca2]i and establish a Ca
2 efflux
profile curve. A calcium chelator, BAPTA was included to block Ca2
influx (27), and the addition of cyclopiazonic acid prevented Ca2 se-
questration into the endoplasmic reticulum by SERCA; this concentra-
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tion was selected based on previous studies (28) and after cyclopiazonic
acid dose response curves were generated in MCF-7 cells (data not
shown). Na/Ca2-free PSS was used throughout the experiment to
prevent the Na/Ca2 exchanger from contributing to Ca2 efflux (27,
29). Hence the rate of decline in [Ca2]i was predominately a measure
of PMCA-mediated free intracellular Ca2 efflux. Experiments were
performed using a NOVOstar® fluorescence microplate reader (BMG
LabTechnologies, Offenburg, Germany). Fluo-4 was excited at 485 nm,
and fluorescence emission was detected at 520 nm. Fluo-4 fluorescence
data points were acquired every 1.5 s. All experiments were performed
at 31  1 °C. Relative changes in [Ca2]i using fluo-4 were determined
by calculations of F/F, where F/F  (Ft  F0)/F0. In this equation, Ft
equals the fluorescence reading at each time point (t), and F0 represents
initial fluorescence at t  0 (30). For each well, where peak [Ca2]i was
obtained within 90.5 s following the addition of ionomycin, the fluores-
cence data corresponding to the 60 s after and including the peak F/F
was fitted to a monoexponential curve as a measure of the rate of
PMCA-mediated free intracellular Ca2 efflux (29).
Statistical Analyses—All data points are presented as means  S.D.,
unless otherwise stated, for the number of replicates (n) indicated.
Meaningful comparisons between groups were analyzed for statistical
significance using a two-sided Student’s t test with significance set at
p  0.05.
RESULTS
PMCA Antisense Induction Suppresses Proliferation of
MCF-7 Tet-off Breast Cancer Cells—To generate a cell line
where PMCA antisense could be tightly controlled and equiv-
alent levels of expression could be obtained, we generated a
MCF-7 Tet-off PMCA antisense cell line, where the removal of
DOX induced PMCA antisense expression (see “Experimental
Procedures”). Based upon initial screening for tetracycline-
regulated -galactosidase expression as a marker for the simul-
taneous expression of PMCA antisense and the sensitivity of
PMCA expression to doxycycline removal, proliferation assays
were conducted for three MCF-7 Tet-off PMCA antisense-
transfected clones. All three clones exhibited inhibition of pro-
liferation upon antisense induction, and one clone (A7) was
selected for more detailed characterization. The effect of anti-
sense expression on proliferation is shown in Fig. 1A for A7.
Controls included identical experiments using parental MCF-7
Tet-off cells (Fig. 1B) and a MCF-7 Tet-off cell line with regu-
lated expression of both -galactosidase and a protein unre-
lated to PMCA (Fig. 1C). The induction of PMCA antisense
(DOX absence) profoundly suppressed the proliferation of
MCF-7 (A7) cells over a period of 13 days (Fig. 1A). The removal
of DOX did not affect the proliferation of the controls (Fig. 1, B
and C).
Effect of PMCA Antisense Induction on PMCA Protein Ex-
pression—To evaluate whether tetracycline-regulated PMCA
antisense inhibits PMCA protein expression, we used immuno-
blotting (Fig. 2) to probe for total PMCA protein using the
non-isoform-specific 5F10 antibody and isoform-specific anti-
bodies to PMCA4, PMCA1, and PMCA2 (31). Immunoblots
were repeated twice for two independent sets of protein iso-
lated from MCF-7 (A7) cells. A representative immunoblot is
shown for total PMCA protein (Fig. 2A). As shown by densi-
tometry measurements, a significant (p  0.005) decrease in
total PMCA protein expression was observed on day 13 in cells
expressing PMCA antisense (DOX absence) compared with no
antisense-expressing cells (DOX presence) (Fig. 2B). Relative
PMCA4 levels increased with days in culture, implicating a
potential role for PMCA4 in proliferation, and this increase was
inhibited in cells expressing antisense (Fig. 2, C and D). By day
13 of growth, PMCA4 protein expression was significantly
(p  0.007) lower in PMCA antisense-induced MCF-7 (A7)
cells, in contrast to the parallel non-induced control (Fig. 2D).
We also showed for the first time, PMCA1 and PMCA2 protein
in MCF-7 cells (Fig. 2, E and G). PMCA1 was only modestly
increased in relative expression with days in culture, which
FIG. 1. Effect of PMCA antisense induction on the prolifera-
tion of MCF-7 cells as monitored by MTS assays. Cells were cul-
tured in either the presence () or absence () of doxycycline (DOX; 100
ng/ml) for up to 13 days. A, MCF-7 Tet-off PMCA antisense cells (clone
A7). B, parental MCF-7 Tet-off cells. C, MCF-7 Tet-off cells with regu-
lated expression of an unrelated protein. The data points in Fig. 1
represent means of four replicate wells  S.D. and are representative of
two independent experiments.
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FIG. 2. Protein expression of total PMCA and specific PMCA isoforms in MCF-7 Tet-off PMCA antisense cells (clone A7). Cells were
cultured in either the presence () or absence () of doxycycline (DOX; 100 ng/ml) and harvested after 3, 7, and 13 days of growth. A, a
representative immunoblot probed for total PMCA protein with the 5F10 antibody. B, the corresponding (to A) densitometry measurements of
bands representing total PMCA normalized to the -actin band in each lane. C, a representative immunoblot probed for PMCA4 protein with the
JA9 antibody. D, the corresponding (to C) densitometry measurements of bands representing PMCA4 normalized to the -actin band in each lane.
E, a representative immunoblot probed for PMCA1 protein with the NR1 antibody. F, the corresponding (to E) densitometry measurements of
bands representing PMCA1 normalized to the -actin band in each lane. G, a representative immunoblot probed for PMCA2 protein with the NR2
antibody. H, the corresponding (to G) densitometry measurements of bands representing PMCA2 normalized to the -actin band in each lane. The
bars in B, D, F, and H represent means  S.E. for n  4 replicates. The asterisk denotes a statistically significant difference (p  0.05).
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was not significantly attenuated by PMCA antisense (Fig. 2, E
and F). Consistent with its likely role in specific cellular func-
tions, such as lactation (19, 32), PMCA2 levels did not alter
with days in culture and proliferation (Fig. 2, G and H).
Effect of PMCA Antisense Induction on SERCA2 Protein
Expression—Due to the regulatory link between PMCA and
SERCA expression (33), we assessed the effects of PMCA anti-
sense-mediated inhibition of MCF-7 cell proliferation on
SERCA2 expression. The modest increase in SERCA2 expres-
sion at day 13 was attenuated when MCF-7 cell proliferation
was inhibited via PMCA antisense (Fig. 3).
PMCA Antisense Induction Alters Cell Cycle Phase Distribu-
tion—We next investigated the effect of PMCA antisense on
cell cycle phase distribution by performing FACS analysis of
DNA content using asynchronous cultures of MCF-7 (A7) cells,
which were grown in either the presence or absence of DOX for
7 and 13 days. Fig. 4 shows (for each growth condition) per-
centages of the total number of cells modeled that were present
in G0/G1, S, or G2/M phases of the cell cycle. There were no
significant differences in the percentage of cells in G0/G1 phase
between MCF-7 (A7) cells grown in either the presence or
absence of DOX for both 7 and 13 days (Fig. 4A). However,
PMCA antisense induction significantly (p  0.005, day 7;
p  0.006, day 13) decreased the percentage of cells present in
S phase (Fig. 4B). PMCA antisense induction also significantly
(p  0.008, day 7; p  0.013, day 13) increased the percentage
of cells in G2/M phase (Fig. 4C). FACS analysis revealed the
absence of a noticeable sub-G0/G1 peak, at either day 7 or 13, in
a set of propidium iodide-stained PMCA antisense-induced
MCF-7 (A7) cells (data not shown).
To further assess the mechanism by which PMCA antisense
induction inhibited the proliferation of MCF-7 (A7) cells, we
conducted BrdUrd pulse-chase experiments. Results (Fig. 5)
are representative of two independent experiments. PMCA an-
tisense induction (DOX absence) in MCF-7 (A7) cells resulted
in fewer BrdUrd-positive cells at 0 h after the BrdUrd pulse
(12–12.9%) compared with the controls (DOX presence; 26–
26.8%). This is consistent with the significant reduction of S
phase cells, as previously shown in Fig. 4B. At 6 h post-pulse,
cells were progressing into G2/M in both control and antisense-
induced groups. At 12 h, the emergence of a BrdUrd-positive
peak with a G0/G1 DNA content in both PMCA antisense-
induced (DOX absence) and -non-induced controls (DOX pres-
ence) indicated that PMCA antisense-induced cells were still
actively transiting S and G2/M phases (Fig. 5A). Thus PMCA
antisense expression in MCF-7 (A7) cells did not result in S or
G2/M phase arrest. At 24 h post-pulse, PMCA antisense induc-
tion resulted in fewer BrdUrd-positive cells with a G0/G1 DNA
content (11.3–12.4%) compared with controls (26.2–27.5%), in-
dicating a slower transition through G2/M phase. No apparent
differences in S and G2/M phase progression were found for
parental MCF-7 Tet-off cells at the 0, 6, and 12 h time points
(data not shown) or the 24 h time point (Fig. 5B).
Induction of PMCA Antisense Inhibits PMCA-mediated Ef-
flux of Free Intracellular Calcium—The effect of PMCA anti-
sense on the primary functional role of PMCA was assessed by
comparing the rate of PMCA-mediated efflux of free intracel-
lular Ca2 between MCF-7 (A7) cells that were cultured either
with or without DOX for 7 days (Fig. 6). Data were obtained by
stimulating Ca2 transients with ionomycin (50–420 nM) and
then monitoring PMCA-mediated declines in [Ca2]i between
pairs of wells containing either PMCA antisense-induced or
-non-induced MCF-7 (A7) cells. Ionomycin was selected to re-
duce the activation of other pathways known to alter PMCA
activity (28, 34). Ca2 transients induced by 300 nM ionomycin
and subsequent declines in DF/F, as a measure of relative
change in [Ca2]i, show that, at this level of PMCA antisense
induction, cells could still recover to basal levels of [Ca2]i after
Ca2 ionophore-induced increases (Fig. 6A). However, cells
expressing PMCA antisense (DOX absence) had a slower rate
of PMCA-mediated free intracellular Ca2 efflux. This is illus-
trated by comparisons of the rate of PMCA-mediated decline in
[Ca2]i between antisense-expressing cells and cells with no
antisense induction at similar levels of peak relative [Ca2]i
(Fig. 6B). To assess the effects of PMCA inhibition on the
calcium homeostasis changes induced by physiological stimuli,
the peak responses to the purinergic receptor activator ATP
(100 mM) were assessed. PMCA inhibition increased peak re-
sponses to this stimulus (Fig. 6C).
PMCA Antisense Induction Alters the Morphology of MCF-7
Tet-off Cells—Phase contrast images of MCF-7 (A7) cells plated
at the same cell density and then grown for 13 days, either in
the presence or absence of DOX, were taken from five random
fields (Fig. 7). PMCA antisense-induced cells (DOX absence)
were subconfluent (Fig. 7B) compared with antisense-non-in-
duced controls (DOX presence) (Fig. 7A). Moreover, a propor-
tion of MCF-7 (A7) cells with PMCA antisense induction exhib-
ited a large, rounded, and flat cell morphology (Fig. 7B), similar
to that we have previously observed for the non-tumorigenic,
“normal” breast cell line MCF-10A (data not shown).
DISCUSSION
Intracellular Ca2 signaling is essential for a diverse array
of cellular functions and regulates processes that control both
FIG. 3. Expression of sarco(endo)plasmic reticulum calcium-ATPase 2 (SERCA2) protein in MCF-7 Tet-off PMCA antisense cells
(clone A7). Cells were cultured in either the presence () or absence () of doxycycline (DOX; 100 ng/ml) and harvested after 3, 7, and 13 days
of growth. A, a representative immunoblot probed for SERCA2 protein with the IID8 antibody. B, the corresponding densitometry measurements
of bands representing SERCA2 normalized to the -actin band in each lane. The bars in B represent means  S.E. for n  4 replicates. The asterisk
denotes a statistically significant difference (p  0.05).
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life and death. PMCA is not merely a mechanism for the main-
tenance of a low resting [Ca2]i. PMCA also plays a role in
shaping the complex dynamics of Ca2 signals (35). The versa-
tility of Ca2 signaling in terms of spatial and temporal regu-
lation is believed to form the basis of how fluctuations in
[Ca2]i are able to encode a diverse array of specific messages
controlling many cellular functions. For instance, changes in
the amplitude and duration of Ca2 signals can mediate the
specificity and efficiency in activating different transcription
factors (36), and PMCA is likely to play a key role in these
events. We sought to investigate the effects of inhibiting
PMCA, a critical regulator of intracellular Ca2 signaling (14),
in MCF-7 human breast cancer cells using a tetracycline-reg-
ulated antisense approach. PMCA antisense induction, at lev-
els that do not completely block recovery of [Ca2]i after stim-
ulation and do not induce cell death, suppresses cell
proliferation, affects cell cycle progression, and alters cell mor-
phology in MCF-7 cells.
PMCA plays an important physiological role in the mam-
mary gland. PMCA4 protein from the rat mammary gland
increases throughout pregnancy up until parturition and then
sharply declines at the start of lactation (19). PMCA2 protein
expression, however, rises during lactation and is particularly
enriched in milk fat globule membranes that originate from
apical membranes of mammary gland secretory cells (19). No-
tably, lactating PMCA2 null mice exhibit deficiencies in the
Ca2 enrichment of milk (32). PMCA is thus likely to be an
important mediator of mammary gland physiology.
We used a tetracycline-regulated antisense approach to as-
sess the functional consequences of PMCA inhibition in the
MCF-7 human breast cancer cell line. This approach was nec-
essary because of the current lack of a highly specific pharma-
cological inhibitor of PMCA. Other commonly used pharmaco-
logical agents include orthovanadate ([VO3(OH)]
2), which is a
general inhibitor of all P-type ATPases (14), and lanthanum
(La3), which has been used to inhibit PMCA-mediated Ca2
efflux (37); but at high concentrations of lanthanum, there may
also be inhibition of Ca2 efflux mediated by the Na/Ca2
exchanger (34). Stable antisense approaches have been used
previously by others to study the functional role of PMCA. For
instance, inhibition of PMCA1 expression in PC6 pheochromo-
cytoma cells via stable antisense hinders neuronal differentia-
tion and neurite extension in response to nerve growth factor
(38). A tetracycline-regulated approach to antisense expression
possesses advantages over the use of antisense oligonucleotides
or transient siRNA transfection. It bypasses the issues sur-
rounding inefficient and variable uptake (39), which may cause
either partial or complete inhibition of expression in some cells.
A transient transfection would make it difficult to confirm
whether decreased proliferation is because of partial target
inhibition or complete inhibition in some cells. Moreover, the
stable expression of antisense under the control of a tetracy-
cline-regulated promoter also allows for the long term inhibi-
tion of protein expression (40), which is of particular relevance
for proteins with relatively long half-lives (41). Indeed, the
half-life of PMCA has been reported to be 	12 days (42).
Moreover, the ability to induce antisense expression only dur-
ing experiments and not during colony selection or culture
maintenance reduces the likelihood of very long term adaptive
changes to signaling pathways.
Our findings show that the induction of PMCA antisense in
the MCF-7 breast cancer cell line profoundly suppresses cell
proliferation (Fig. 1A), being neither a nonspecific effect of DOX
removal from the culture medium (Fig. 1B) nor a random effect
of expression from a tetracycline-regulated promoter (Fig. 1C).
Immunoblot densitometry measurements indicated that
FIG. 4. Effect of PMCA antisense induction on cell cycle phase
distribution as determined by FACS analysis of MCF-7 Tet-off
PMCA antisense cells (clone A7). Cells were cultured in either the
presence () or absence () of doxycycline (DOX; 100 ng/ml) and har-
vested after 7 and 13 days of growth. The panels represent results for
the percentage of the total number of cells analyzed that were present
in G0/G1 phase (A), S phase (B), and G2/M phase (C) of the cell cycle. The
bars are indicative of means  S.D. for three independent experiments.
The asterisk denotes a statistically significant difference (p  0.05).
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PMCA antisense induction inhibited total PMCA protein ex-
pression (Fig. 2, A and B). Our studies also demonstrated for
the first time PMCA1, PMCA4, and PMCA2 protein expression
in MCF-7 cells. This places the well characterized MCF-7 cell
line as an outstanding tool to explore the role of individual
PMCA isoforms in specific signaling pathways and functions.
The relatively long half-life of PMCA (42) may account for a
significant difference in the PMCA protein level being evident
only after extended days of culture and suggests that the inhi-
bition of new PMCA protein synthesis regulates the observed
effect on cell proliferation. Even when PMCA-mediated free
intracellular Ca2 efflux is inhibited to levels that allow recov-
ery of [Ca2]i (Fig. 6A), we saw dramatically reduced cell pro-
liferation, identifying PMCA as a potential drug target in
breast cancer. Indeed, the non-estrogen-mediated effects of
tamoxifen have been likened to the augmentation of Ca2
responses (43), an effect which would also arise from the inhi-
bition of PMCA.
FIG. 5. Effect of PMCA antisense in-
duction on cell cycle phase progres-
sion as determined by dual 5-bro-
mo-2-deoxyuridine (BrdUrd)- and
7-amino-actinomycin D (7-AAD)-
stained FACS analysis of MCF-7 Tet-
off PMCA antisense cells (clone A7).
Cells were cultured in either the presence
() or absence () of doxycycline (DOX;
100 ng/ml) for 7 days, pulsed with BrdUrd
10 M for 1 h, and then harvested 0, 3, 6,
12, and 24 h post-BrdUrd pulse. A, results
are shown for MCF-7 Tet-off PMCA anti-
sense cells (clone A7) at 0, 6, 12, and 24 h
after the BrdUrd pulse. B, results are
shown for parental MCF-7 Tet-off cells at
24 h after the BrdUrd pulse. The y-axis
(anti-BrdUrd fluorescein isothiocyanate
(FITC)) indicates whether cells are synthe-
sizing DNA or have undergone DNA syn-
thesis with the incorporation of Brd-
Urd. The x-axis (7-AAD) indicates whether
cells have a G0/G1 or G2/M DNA content.
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FACS analysis showed that PMCA antisense induction did
not result in apparent apoptotic cell death compared with non-
induced controls; rather antisense affected the S and G2/M
phases of the cell cycle. FACS analysis of DNA content alone
(Fig. 4) did not indicate whether this effect was because of a
slow down in cell cycle progression or an arrest in a particular
phase. BrdUrd pulse-chase studies showed that the duration
for which cells resided in the G2/M phase was increased by
PMCA antisense and that cells were still able to transit S and
G2/M phases of the cell cycle (Fig. 5). Thus the effect of PMCA
antisense on the cell cycle involves changes in cell cycle kinetics
rather than cell cycle arrest. Phase contrast images depicting
confluence of cell cultures and cell morphology (Fig. 7) not only
confirm that PMCA antisense inhibits cell proliferation but
also results in some cells acquiring an enlarged, rounded, and
flattened appearance characteristic of normal breast epithelia
FIG. 6. PMCA-mediated efflux of free intracellular calcium
and peak ATP responses as determined by relative changes in
fluo-4 fluorescence (F/F). MCF-7 Tet-off PMCA antisense cells
(clone A7) were cultured for 7 days, either in the presence () or
absence () of doxycycline (DOX; 100 ng/ml) loaded with the intracel-
lular Ca2 indicator fluo-4 and then PMCA-mediated free intracellular
Ca2 efflux and peak ATP responses were assessed. A, example traces
of Ca2 transients induced by 300 nM ionomycin are shown for a pair of
wells housing cells that were grown either in the presence of DOX
(DOX; no antisense) or absence of DOX (DOX; antisense). The rate
of decline in F/F, after reaching peak F/F, is a relative measure of
PMCA-mediated free intracellular Ca2 efflux. B, rates of PMCA-me-
diated decline in F/F were plotted against peak F/F values for valid
comparisons of PMCA-mediated Ca2 efflux rates in antisense-induced
and -non-induced cells. Data points in B are means  S.E. Numbers of
replicates for each ionomycin concentration used are as follows: 6 at 50
nM, 14–18 at 100 nM, 23–26 at 175 nM, 34 at 300 nM, and 35–38 at 420
nM. C, peak F/F values induced by ATP at 100 M are shown for cells
that were grown either in the presence of doxycycline (DOX; no
antisense) or absence of doxycycline (DOX; antisense). Bars represent
mean  S.E. (n  6).
FIG. 7. Assessment of cell morphology as seen by phase con-
trast microscopy after the induction of PMCA antisense. MCF-7
Tet-off PMCA antisense cells (clone A7) were plated onto coverslips
placed in a 6-well plate at 1.8  104 cells/well and then cultured in
either the presence () or absence () of doxycycline (DOX; 100 ng/ml).
After 13 days of growth, images of cells at 200 magnification were
taken from five random fields. A, the panels on the left are images of
cells grown in the presence of doxycycline (DOX; no antisense). B, the
panels on the right are images of cells grown in the absence of doxycy-
cline (DOX; antisense).
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(44). The effect of PMCA antisense is likely to act on the G2/M
phase to slow down cell cycle progression and may even induce
senescence in breast epithelial cells.
To evaluate whether the induction of PMCA antisense af-
fected PMCA function and not only protein expression, we
assessed the relative rates of PMCA-mediated intracellular
Ca2 efflux in PMCA antisense-expressing and -non-express-
ing MCF-7 cells (Fig. 6B). The suppression of cell proliferation
by PMCA antisense induction correlated with the inhibition of
PMCA-mediated intracellular Ca2 efflux. Although PMCA an-
tisense altered PMCA-mediated intracellular Ca2 efflux, this
degree of antisense induction did not affect the apparent ability
of the cell to eventually recover basal intracellular Ca2 levels
after ionomycin-induced increases in [Ca2]i (Fig. 6A). This
may explain why suppression of cell proliferation was observed
upon PMCA antisense induction, without the concomitant
presence of noticeable cell death. Indeed ATP-induced calcium
signaling remained during partial PMCA inhibition, although
as predicted, when calcium efflux is reduced, peak calcium
responses were augmented (Fig. 6C). Collectively, our results
suggest that moderate changes in PMCA-mediated Ca2 efflux
can lead to profound cellular consequences, despite the absence
of major deleterious effects on global intracellular Ca2 homeo-
stasis. It also supports the possibility of how alterations in
PMCA function may affect the kinetics of Ca2 signals in
specifically regulating various cellular processes such as pro-
liferation (3). The complex dynamic aspects of intracellular
Ca2 signaling in regulating transcription factors has been an
area of active research (1, 2) and represents a link by which
PMCA-mediated modulation of Ca2 signaling could control
gene transcription and cell phenotype. Indeed, frequency mod-
ulation of Ca2 signals can regulate the activity of nuclear
factor B (NFB) (45), a key transcription factor that is impor-
tant in the control of proliferation in lymphocytes and is also
abnormally expressed in breast cancer (46).
There is a growing body of evidence suggesting PMCA plays
important functional roles in the breast. Our data support this
notion, and although inhibition of PMCA-mediated Ca2 efflux
may limit breast cancer cell line proliferation alone, compro-
mised PMCA function may be able to augment cytotoxic Ca2
responses together with other existing anti-tumor agents like
tamoxifen (43). This and the consequences of inhibiting specific
PMCA isoforms in MCF-7 cells warrant further investigation.
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